Neues von LAMP...Es geht weiter - 500 Beiträge pro Seite

[HolgiNils]

LAM Pharmaceutical Corp. - LAM IPM(TM) Wound Gel Product Status Update onPre-Marketing Notification 510(k) Filed With FDA
LEWISTON, N.Y., Mar 19, 2002 (Canada NewsWire via COMTEX) -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM), http://www.lampharm.com issued the following update concerning the current status of LAM IPM(TM) Wound Gel. On January 31, 2002 LAM Pharmaceutical, Corp. filed a 510(k) pre-market notification with the Food and Drug Administration in the United States for LAM IPM(TM) Wound Gel.

The FDA has assigned the following number to the 510(k) pre-market notification - K020325.

Formerly known as "LAM Ulcer Matrix," the product is now known as LAM IPM(TM) Wound Gel.

Under F.D.A. guidelines, the Company expects to receive a decision by April 30, 2002 regarding the status of LAM IPM(TM) Wound Gel`s suitability to be marketed.

Under supervision of a healthcare professional, LAM IPM(TM) Wound Gel is suitable for exuding wounds such as:



- Diabetic ulcers
- Leg ulcers
- Pressure ulcers
- Management of wounds that are prone to bleeding, such as wounds that
have been mechanically or surgically debrided.

LAM`s Chief Executive Officer, Alan Drizen, said, "We are excited and most proud that eight years of research and development have brought us to this important juncture where the results of our hard work are allowing us to commercialize our proprietary and patented technologies."

As promised, the company has delivered on completing the following important steps to help ensure the success of its first commercial product. These include:



- Richard Brokenshire joined LAM in the newly created position as
Vice President, Sales & Marketing.
- LAM signed an agreement to register IPM(TM) Wound Gel in Mexico.
- Exygen Research was appointed as quality control specialists and
will provide analytical and other technical services to assist in
the commercialization of LAM`s entire product portfolio.
- LAM signed a marketing agreement with RxCentric Inc. of New York
City.
- Packaging design for IPM(TM) Wound Gel has been completed.

In the Company`s opinion, revenue forecasts of US$ 27.0 million for 2003 and US$ 50.0 million for 2004 calendar year are both realistic and achievable, given the size (U.S. 2.5 billion plus) of the wound care market segment on which LAM IPM(TM) Wound Gel impacts.

"This 510(k) submission is a critical milestone for LAM Pharmaceutical, Corp.," Joseph Slechta, President & Chief Operating Officer commented. "With anticipated FDA clearance of LAM IPM(TM) Wound Gel, LAM has successfully initiated manufacturing, marketing and distribution channels which will position the Company to begin sales of the product in the early part of the third quarter 2002. Revenues should commence within this time frame. Successful introduction of this product within our stated timetable should lead to growing confidence in the investing community of LAM`s ability to execute its growth strategy. Other significant products are well past the planning stage and should incrementally add to our revenues and earnings in 2003 and beyond," Slechta concluded.

About LAM Pharmaceutical, Corp.

LAM Pharmaceutical, Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of nine U.S. issued patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology combines with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible and thus prolonging therapeutic activity.

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin and joints of bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentration in fetal skin where wound healing is rapid and leaves little scarring.

LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).

As of December 31, 2001, LAM had nine issued patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have subsequently been filed on a global basis.

The Company`s list of products under development include the following:

LAM IPM(TM) -- Extreme Dry Skin Formula -- A gel formula designed to saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely dry skin.

LAM IPM(TM) -- Female Sexual Dysfunction Matrix -- a product that provides enhanced lubrication while also allowing the external structures of the female genitalia to be flushed with greater blood supply.

LAM IPM(TM) -- Motion Sickness Matrix -- a product currently under development, which is a topically applied delivery system, using a patch, of a well-known motion sickness drug.

LAM IPM(TM) -- Arthritic Pain Matrix -- is a clear aqueous gel that contains a well proven off patent drug.

For more information please visit our website at http://www.lampharm.com or send us an e-mail at [e-mail] to receive the latest information and press releases.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.



Company Contact: Anthony Vespa
Toll Free in N. America (877) LAM-7717
[phone]
Tel [phone]
Fax [phone]
Website: http://www.lampharm.com


Press Contact: Barry S. Kaplan
[phone]
FAX: [phone]
[e-mail]

VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=12673


CONTACT: For further information: Anthony Vespa of LAM Pharmaceutical, Corp.,

[phone], fax: [phone]; or Barry S. Kaplan, [phone],
fax: [phone], smallkap(at)aol.com, for LAM Pharmaceutical, Corp.

URL: Web site: http://www.lampharm.com
News release via Canada NewsWire, Toronto 416-863-9350

Copyright (C) 2002 CNW, All rights reserved

[HolgiNils]

TheSUBWAY.com Announces Investment Opinion: Time to Go?
WESTON, Fla., Mar 21, 2002 (BUSINESS WIRE) -- Keep an eye on LAM Pharmaceutical Corp. (OTCBB:LAMP). The company just released big news. LAMP is down from almost $6.50 and could be a huge gainer in the short term. Other stock market standouts include NVIDIA Corporation (Nasdaq:NVDA), down 10% on 19 million shares after launching new Select Builder Program, Red Hat Inc. (Nasdaq:RHAT), down 18% on 9 million shares after reporting Q4 and Year End Results, Applied Micro Circuits (Nasdaq:AMCC), down 7% on 5 million shares after news of new product and Gold Fields Limited (Nasdaq:GOLD), up 6% on 2.2 million shares.

"In a unanimous decision among Fed members, the central bank opted to leave interest rates unchanged, with the fed funds target remaining at 1.75 percent Tuesday afternoon. The key lending rate dropped below 2 percent in December, after the Federal Reserve cut interest rates for the 11th time in just over one year`s time in an unprecedented bid to revive the ailing U.S. economy," stated Peter Antipatis. Continued in TheSUBWAY.com`s daily commentary at http://www.TheSUBWAY.com

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (one hundred and twenty five thousand lamp) CRG intends to sell its shares. CRG has sold approximately eighty five thousand lamp shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.


CONTACT: Capital Research Group Inc., Weston

Charles T. Tamburello, 954/217-9555
Fax: [phone]
Email: [e-mail]

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

[Escape11]

LAM Pharmaceutical, Corp.: Anmeldung zur 510(k) “pre-market notification bestätigt


Dienstag, 19. März 2002 17:52


Heute wurde in New York bekannt gegeben, dass die am 31. Jänner, von LAM Pharmaceutics, Corp. (WKN 631629, Frankfurt) beantragte 510(k) “pre-market notification, bestätigt wurde. Früher bekannt als “LAM Ulcer Matrix”, firmiert das Produkt jetzt unter dem Namen „LAM IPM™ Wound Gel“. Nun wird nur noch eine Entscheidung bezüglich der Zulassung des Wound Gels zum Markt erwartet. Diese Entscheidung soll bis zum 30.April 2002 getroffen werden.

Das Wound Gel soll sich vor allem für diabetische Wunden, Fußwunden und Fußgeschwüre, Druck- und Druckstellen-Wunden sowie für die Heilung von Wunden, die zu Blutungen und Absonderungen neigen, eigenen.

Um den Erfolg des ersten Eigenproduktes zu gewährleisten, wurden folgende Schritte und Pläne realisiert: Richard Brokenshire wurde für die neu geschaffene Position ,,Vice President, Sales & Marketing’’ engagiert, LAM unterzeichnete ein Abkommen, um IPM™ Wound Gel in Mexiko zu registrieren lassen zu können, Exygen Research wurde zur Qualitätskontrolle herangezogen und steht auch weiterhin mit seinem Fachwissen bei der Platzierung des gesamten Produkteportfolios von LAM zur Verfügung, weiters hat LAM mit der RxCentric Inc., New York City, einen Marketing-Vertrag abgeschlossen und der Entwurf zum Verpackungsdesign für IPM™ Wound Gel wurde erfolgreich abgeschlossen.

Die Aktie notiert derzeit bei 0,80 Euro, was einem Minus von 2,44% entspricht.